<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04996719</url>
  </required_header>
  <id_info>
    <org_study_id>21-003837</org_study_id>
    <nct_id>NCT04996719</nct_id>
  </id_info>
  <brief_title>Effect of Rapamycin to Improve Cardiac Function in Frail Older Adults</brief_title>
  <official_title>Effect of Rapamycin to Improve Cardiac Function in Frail Older Adults With Heart Failure With Preserved Ejection Fraction: A Pilot and Proof-of-Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to see if the drug rapamycin will improve the heart's ability&#xD;
      to pump by improving your oxygen consumption.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a pilot, proof-of-concept study. Patients 60 years or older with invasively&#xD;
      proven HFpEF or have definite HFpEF as determined by the 2 established scores and frailty&#xD;
      (positive screen for computable phenotype), will be approached for enrollment. Subjects&#xD;
      meeting screening criteria following written informed consent including hsCRP levels ≥2mg/L&#xD;
      will undergo treatment with open label rapamycin. Efficacy outcomes will be measured at&#xD;
      baseline and at 6 months. Safety will be assessed by remote video monitoring weekly for 1&#xD;
      month, then monthly for 5 months till the end of the study. We will also measure trough&#xD;
      rapamycin levels (≤4ng/mL) twice-a-month for the first month and then monthly for 5 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change cardiopulmonary reserve capacity by improving peak VO2 with rapamycin</measure>
    <time_frame>6 months</time_frame>
    <description>In this pilot, proof-of-concept study, we hypothesize that in older adults (≥60 years) with HFpEF who are frail with increased hsCRP (≥2mg/L), chronic rapamycin administration will change their cardiopulmonary reserve capacity by improving peak VO2.Primary safety objective is the safety of rapamycin.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Rapamycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>find safe doses for patients who have heart failure with preserved ejection fraction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamune</intervention_name>
    <description>We will start the dose at 0.5mg capsule every other day for 2 weeks. If participants tolerate this dose and trough blood levels are (≤4ng/mL), the dose of rapamycin will be increased to 0.5mg daily for the duration of the study. If necessary, dose can remain at 0.5 mg every other day, depending on the trough level. To avoid immunosuppression, we will target lower dose of rapamycin, maintain lower trough serum levels (≤4ng/mL).</description>
    <arm_group_label>Rapamycin</arm_group_label>
    <other_name>Rapamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥60 years&#xD;
&#xD;
          -  Diagnosis of HFpEF by either H2FEPF score of 6-9 or HFA-PEFF score of 5-6, or&#xD;
             invasively confirmed diagnosis of HFpEF (resting pulmonary capillary wedge pressure&#xD;
             ≥15mmHg or ≥25mmHg with exercise).&#xD;
&#xD;
          -  Diagnosis of computable phenotype of frailty rests on screening questions about&#xD;
             ability to climb two flights of stairs, activities of daily living, living&#xD;
             environment, wearing of dentures/hearing aids, and whether the patient uses assistive&#xD;
             devices.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Reduced ejection fraction (≤50%) with or without prior history of myocardial&#xD;
             infarction&#xD;
&#xD;
          -  Acute coronary syndrome &lt;3 months&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus (HbA1C&gt;8)&#xD;
&#xD;
          -  Uncontrolled hypertension (&gt;160/100mmHg, despite 3 antihypertensive medications)&#xD;
&#xD;
          -  Nephrotic syndrome or eGFR &lt;30mL/min/1.73m2&#xD;
&#xD;
          -  Cirrhosis&#xD;
&#xD;
          -  Hepatitis B/C positive&#xD;
&#xD;
          -  Elevated lived enzymes (AST/ALT&gt;3ULN&#xD;
&#xD;
          -  Prior malignancy other than basal cell carcinoma&#xD;
&#xD;
          -  History of ongoing, chronic or recurrent infectious disease&#xD;
&#xD;
          -  Suspected/proven immunocompromised state&#xD;
&#xD;
          -  Uncontrolled hyperlipidemia (fasting TG &gt;400 mg/dL (&gt;4.5 mmol/L) or total cholesterol&#xD;
             &gt;300 mg/dL (&gt;7.8 mmol/L) despite maximum lipid lowering therapy&#xD;
&#xD;
          -  Class IV HF symptoms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mandeep Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monica L Olson</last_name>
    <phone>507-255-2649</phone>
    <email>olson.monica2@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Spenta</last_name>
      <phone>507-422-0780</phone>
      <email>speltz.brenda@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Mandeep Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Mandeep Singh</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

